Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. - Jamroze A; Liu X; Hou S; Jess Li W; Yu H; Tracz A; Jacobi J; Li Q; Nastiuk K; Chen X; Huang J; Lin K; et al. (Signal transduction and targeted therapy, 2026)